Xeris Biopharma Holdings Inc (XERS) (Q3 2026) Earnings Call Highlights: Revenue Surges 44% as ... - Yahoo Finance
Xeris's third-quarter total revenue rose 44% year over year to $107.2 million, while net product revenue increased 43% to $106.3 million. [[fact-at9a5g8ny]] Recorlev net revenue grew 93% year over year to $71.5 million. [[fact-7ob9hspxc]] Adjusted EBITDA improved 77% year over year to $30.8 million, and net income was $11.3 million versus $0.6 million a year earlier. [[fact-99jhskk52]] The company raised full-year 2026 revenue guidance to $395 million-$405 million and increased its 2030 revenue outlook from $750 million to more than $1 billion. [[fact-y1hm8ixxl]] G-Voq net revenue fell year over year to $21.7 million from $25.2 million, which the company attributed to a one-time $4 million gross-to-net adjustment in the Medicaid channel. [[fact-6m4wnh6p0]]